ICU Medical Inc./DE (ICUI) is a global medical device company that specializes in the development, manufacture, and sales of innovative medical devices used in vascular therapy, critical care, and oncology applications. The company is named after its founder, Dr. George A. Lopez, who invented the first "disposable medical connector" while working as an intern in the intensive care unit (ICU), which is where the company's name - ICU Medical - originated.
Founded in 1984 and headquartered in San Clemente, California, the company primarily creates products that enhance patient outcomes by helping to prevent bloodstream infections and protect healthcare workers from exposure to infectious diseases or hazardous drugs.
ICU Medical Inc.'s product line includes the Clave, a needle-free connection device designed to maintain a closed system during the administration of IV therapy. It also offers intravenous catheters, closed-system transfer devices for hazardous drugs, and custom infusion sets. Additionally, ICU Medical Inc. provides products for patient monitoring, such as disposable pressure transducer systems and hemodynamic monitoring systems.
ICUI is well known for its consistent focus on improving and simplifying the infusion therapy process, ensuring safety for both patients and healthcare professionals. For instance, its closed system transfer device, the ChemoLock and ChemoClave systems, are designed to prevent exposure to hazardous drugs during drug preparation, administration, and disposal, improving the safety of healthcare workers who frequently handle these medications.
One of the company's landmark achievements was in 2016, when it purchased the Hospira Infusion Systems business from Pfizer for $1 billion. This acquisition extended ICU Medical's product offering to include IV pumps and solutions, further validating its commitment to becoming a comprehensive player in the IV therapy market.
Today, ICU Medical Inc. is among the leaders in its field, securing its position in the healthcare sector with its commitment to innovation, patient safety, and superior product quality. The steadfast focus on research and development, along with strategic acquisitions and partnerships, has propelled ICU Medical Inc. to continued success, reflected in its robust market presence and stellar reputation in the medical device industry.
Furthermore, ICU Medical Inc./DE believes in fulfilling its corporate responsibility by committing to sustainable practices that consider the environment, their employees, and society. These efforts incorporate everything from transparency in their manufacturing and operational processes to employee welfare and community outreach programs.
With the ongoing COVID-19 pandemic further emphasizing the need for secure and efficiency-driven healthcare solutions, ICU Medical Inc./DE is positioned even more firmly to respond to these challenges. Their products and solutions are at the forefront of delivering safe and effective medical care - a testament to their determination in setting new standards in healthcare delivery and patient safety.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Argus has issued a stock forecast for ICU Medical, Inc. (ICUI), raising its target price to $169.00 from a current price of $166.02. The report, dated September 23, 2026, describes ICU Medical as a California-based pure-play infusion therapy company.
ICU Medical Inc (ICUI) shares recently rose 3.7% to $160.98, significantly above its GF Value™ estimate of $121.40, indicating it is "Significantly Overvalued." The company has a strong GF Score™ of 83/100, driven by profitability and momentum, but its valuation rank is weak, and insiders have sold $8.3 million in shares with no buying activity, suggesting caution for investors.
Otsuka ICU Medical LLC has issued a recall for one lot of 0.9% Sodium Chloride Injection, USP (saline) after a customer discovered a bag of concentrated potassium chloride inside a saline-labeled overwrap. The recall, affecting lot 1042188, targets hospitals and clinics, though no adverse events have been reported. The primary safeguard against accidental administration is the clear labeling on the inner potassium chloride bag, requiring healthcare professionals to check before use.
ICU Medical's CFO, Brian Michael Bonnell, sold 6,381 shares of common stock for $1.1 million on September 1, 2026, as part of a pre-established Rule 10b5-1 trading plan. Despite the sale, Bonnell retains 56,062 shares valued at approximately $9.5 million, indicating continued confidence in the company. The sale is considered routine and not a cause for alarm, especially given ICU Medical's recent positive financial performance and stock growth.
An insider at ICU Medical, Inc. sold shares worth $1,116,675, as disclosed in a recent SEC filing. This transaction follows other insider share sales from the company, including one on August 31st for $1,608,143. ICU Medical specializes in medical products for infusion therapy, vascular access, and vital care.
An insider at ICU Medical, Inc. sold shares valued at $1,608,143, according to a recent SEC filing. This follows previous insider share sales reported in August, including one worth $401,209 and another for $1,633,404. The company recently announced Q2 2026 earnings that exceeded estimates and revised its full-year 2026 guidance upwards.